- Press Releases
- Notices
Press Releases To List
-
- Oct.09.2025R & D
- Ono Announces ONO-4578 (EP4 antagonist) in Combination with Opdivo and Chemotherapy Met the Primary Endpoint in a Phase 2 Clinical Trial in Patients with Certain Gastric Cancer
-
- Oct.09.2025R & D
- Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy
-
- Sep.30.2025R & D
- Ono Submits an Application for Approval of Cenobamate (ONO-2017), Antiseizure Medications in Japan
-
- Sep.26.2025Corporate
- Support for Typhoon Relief Efforts in Eastern Taiwan
-
- Sep.18.2025R & D
- Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Notices To List
-
- Sep.29.2025Corporate
- Corporate Report 2025 has been released.
-
- Aug.04.2025Corporate
- Notice about Posting of the Business Result Meeting for FY2025 Q1 - Script
-
- Jun.20.2025Corporate
- Voting Results (Extraordinary Report) of the 77th Ordinary General Shareholders’ Meeting
-
- Jun.19.2025Corporate
- Notice to Resolutions Passed at The 77th Ordinary General shareholders’ Meeting
-
- Jun.11.2025Corporate
- Notice about Posting of R&D Day - ASCO PROSPECT Study Data Presentation - Script
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
